1. |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
|
2. |
World Health Organization. Global health estimates 2020: deaths by cause, age, sex, by country and by region, 2000-2019.
|
3. |
Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. Hum Mol Genet, 2018, 27(20): 3641-3649.
|
4. |
Chen J, Spracklen CN, Marenne G, et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet, 2021, 53(6): 840-860.
|
5. |
Lindström S, Wang L, Feng H, et al. Genome-wide analyses characterize shared heritability among cancers and identify novel cancer susceptibility regions. J Natl Cancer Inst, 2023, 115(6): 712-732.
|
6. |
Birney E. Mendelian randomization. Cold Spring Harb Perspect Med, 2022, 12(4): a041302.
|
7. |
Ference BA, Holmes MV, Smith GD. Using Mendelian randomization to improve the design of randomized trials. Cold Spring Harb Perspect Med, 2021, 11(7): a040980.
|
8. |
Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med, 2008, 27(8): 1133-1163.
|
9. |
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum, 2004, 83: 1-1438.
|
10. |
Larsson SC, Burgess S. Appraising the causal role of smoking in multiple diseases: a systematic review and meta-analysis of Mendelian randomization studies. EBioMedicine, 2022, 82: 104154.
|
11. |
Bowden SJ, Doulgeraki T, Bouras E, et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Med, 2023, 21(1): 274.
|
12. |
Larsson SC, Carter P, Kar S, et al. Smoking, alcohol consumption, and cancer: a Mendelian randomisation study in UK Biobank and international genetic consortia participants. PLoS Med, 2020, 17(7): e1003178.
|
13. |
Liu S, Feng S, Du F, et al. Association of smoking, alcohol, and coffee consumption with the risk of ovarian cancer and prognosis: a Mendelian randomization study. BMC Cancer, 2023, 23(1): 256.
|
14. |
Fukushima Y, Takahashi Y, Kishimoto Y, et al. Consumption of polyphenols in coffee and green tea alleviates skin photoaging in healthy Japanese women. Clin Cosmet Investig Dermatol, 2020, 13: 165-172.
|
15. |
Hashimoto T, He Z, Ma WY, et al. Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res, 2004, 64(9): 3344-3349.
|
16. |
Carter P, Yuan S, Kar S, et al. Coffee consumption and cancer risk: a Mendelian randomisation study. Clin Nutr, 2022, 41(10): 2113-2123.
|
17. |
Ellingjord-Dale M, Papadimitriou N, Katsoulis M, et al. Coffee consumption and risk of breast cancer: a Mendelian randomization study. PLoS One, 2021, 16(1): e0236904.
|
18. |
Lumsden AL, Mulugeta A, Hyppönen E. Milk consumption and risk of twelve cancers: a large-scale observational and Mendelian randomisation study. Clin Nutr, 2023, 42(1): 1-8.
|
19. |
Larsson SC, Mason AM, Kar S, et al. Genetically proxied milk consumption and risk of colorectal, bladder, breast, and prostate cancer: a two-sample Mendelian randomization study. BMC Med, 2020, 18(1): 370.
|
20. |
Ong JS, Derks EM, Eriksson M, et al. Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses. Int J Cancer, 2021, 148(6): 1338-1350.
|
21. |
Rumgay H, Shield K, Charvat H, et al. Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study. Lancet Oncol, 2021, 22(8): 1071-1080.
|
22. |
Richmond RC, Anderson EL, Dashti HS, et al. Investigating causal relations between sleep traits and risk of breast cancer in women: Mendelian randomisation study. BMJ, 2019, 365: l2327.
|
23. |
Yang X, Wang J, Wang H. Association between sleep traits and primary liver cancer: a Mendelian randomization analysis. Eur J Clin Invest, 2023, 53(8): e14002.
|
24. |
Wang J, Tang H, Duan Y, et al. Association between sleep traits and lung cancer: a Mendelian randomization study. J Immunol Res, 2021, 2021: 1893882.
|
25. |
Yuan S, Mason AM, Titova OE, et al. Morning chronotype and digestive tract cancers: Mendelian randomization study. Int J Cancer, 2023, 152(4): 697-704.
|
26. |
Titova OE, Michaëlsson K, Vithayathil M, et al. Sleep duration and risk of overall and 22 site-specific cancers: a Mendelian randomization study. Int J Cancer, 2021, 148(4): 914-920.
|
27. |
Chan II, Kwok MK, Schooling CM. Blood pressure and risk of cancer: a Mendelian randomization study. BMC Cancer, 2021, 21(1): 1338.
|
28. |
Qu Y, Chen L, Guo S, et al. Genetic liability to multiple factors and uterine leiomyoma risk: a Mendelian randomization study. Front Endocrinol (Lausanne), 2023, 14: 1133260.
|
29. |
Lu Y, Gentiluomo M, Lorenzo-Bermejo J, et al. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. J Med Genet, 2020, 57(12): 820-828.
|
30. |
Au Yeung SL, Schooling CM. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study. BMJ Open Diabetes Res Care, 2019, 7(1): e000872.
|
31. |
Yang H, Dai H, Li L, et al. Age at menarche and epithelial ovarian cancer risk: a meta-analysis and Mendelian randomization study. Cancer Med, 2019, 8(8): 4012-4022.
|
32. |
Lu Y, Tang H, Huang P, et al. Assessment of causal effects of visceral adipose tissue on risk of cancers: a Mendelian randomization study. Int J Epidemiol, 2022, 51(4): 1204-1218.
|
33. |
Cornish AJ, Law PJ, Timofeeva M, et al. Modifiable pathways for colorectal cancer: a Mendelian randomisation analysis. Lancet Gastroenterol Hepatol, 2020, 5(1): 55-62.
|
34. |
Vithayathil M, Carter P, Kar S, et al. Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: a Mendelian randomisation study. PLoS Med, 2021, 18(7): e1003706.
|
35. |
Lu L, Wan B, Zeng H, et al. Body mass index and the risk of basal cell carcinoma: evidence from Mendelian randomization analysis. PeerJ, 2023, 11: e14781.
|
36. |
Gui L, He X, Tang L, et al. Obesity and head and neck cancer risk: a Mendelian randomization study. BMC Med Genomics, 2023, 16(1): 200.
|
37. |
Jarvis D, Mitchell JS, Law PJ, et al. Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. Br J Cancer, 2016, 115(2): 266-272.
|
38. |
Henson DE, Block G, Levine M. Ascorbic acid: biologic functions and relation to cancer. J Natl Cancer Inst, 1991, 83(8): 547-550.
|
39. |
Villagran M, Ferreira J, Martorell M, et al. The role of vitamin C in cancer prevention and therapy: a literature review. Antioxidants (Basel), 2021, 10(12): 1894.
|
40. |
Yin L, Yan H, Chen K, et al. Diet-derived circulating antioxidants and risk of digestive system tumors: a Mendelian randomization study. Nutrients, 2022, 14(16): 3274.
|
41. |
Larsson SC, Mason AM, Vithayathil M, et al. Circulating vitamin C and digestive system cancers: Mendelian randomization study. Clin Nutr, 2022, 41(9): 2031-2035.
|
42. |
Zhang X, Zhao H, Man J, et al. Investigating causal associations of diet-derived circulating antioxidants with the risk of digestive system cancers: a Mendelian randomization study. Nutrients, 2022, 14(15): 3237.
|
43. |
Dimitrakopoulou VI, Tsilidis KK, Haycock PC, et al. Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. BMJ, 2017, 359: j4761.
|
44. |
Chen X, Song S, Shi J, et al. Evaluating the effect of body mass index and 25-hydroxy-vitamin D level on basal cell carcinoma using Mendelian randomization. Sci Rep, 2023, 13(1): 16552.
|
45. |
Ong JS, Gharahkhani P, An J, et al. Vitamin D and overall cancer risk and cancer mortality: a Mendelian randomization study. Hum Mol Genet, 2018, 27(24): 4315-4322.
|
46. |
He Y, Zhang X, Timofeeva M, et al. Bidirectional Mendelian randomisation analysis of the relationship between circulating vitamin D concentration and colorectal cancer risk. Int J Cancer, 2022, 150(2): 303-307.
|
47. |
Dong J, Gharahkhani P, Chow WH, et al. No association between vitamin D status and risk of Barrett’s esophagus or esophageal adenocarcinoma: a Mendelian randomization study. Clin Gastroenterol Hepatol, 2019, 17(11): 2227-2235.
|
48. |
Dai Y, Chen Y, Pu Y, et al. Circulating vitamin D concentration and risk of 14 cancers: a bidirectional Mendelian randomization study. J Cancer Res Clin Oncol, 2023, 149(17): 15457-15467.
|
49. |
Wang Y, Jia Z, Wang Q, et al. Amino acids and risk of colon adenocarcinoma: a Mendelian randomization study. BMC Cancer, 2023, 23(1): 1041.
|
50. |
Xu H, Wang X, Xu X, et al. Association of plasma branched-chain amino acid with multiple cancers: a Mendelian randomization analysis. Clin Nutr, 2023, 42(12): 2493-2502.
|
51. |
Kong X, Yu J, Zhu Z, et al. Causal associations of histidine and 12 site-specific cancers: a bidirectional Mendelian randomization study. Mol Genet Genomics, 2023, 298(6): 1331-1341.
|
52. |
Liyanage UE, Ong JS, An J, et al. Mendelian randomization study for genetically predicted polyunsaturated fatty acids levels on overall cancer risk and mortality. Cancer Epidemiol Biomarkers Prev, 2019, 28(6): 1015-1023.
|
53. |
Orho-Melander M, Hindy G, Borgquist S, et al. Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study. Int J Epidemiol, 2018, 47(2): 495-505.
|
54. |
Haycock PC, Borges MC, Burrows K, et al. The association between genetically elevated polyunsaturated fatty acids and risk of cancer. EBioMedicine, 2023, 91: 104510.
|
55. |
Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. Nature, 2018, 558(7708): 73-79.
|
56. |
Mälarstig A, Grassmann F, Dahl L, et al. Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation. Nat Commun, 2023, 14(1): 7680.
|
57. |
Rodier F, Coppé JP, Patil CK, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol, 2009, 11(8): 973-979.
|
58. |
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell, 2010, 140(6): 883-899.
|
59. |
Rokavec M, Öner MG, Hermeking H. lnflammation-induced epigenetic switches in cancer. Cell Mol Life Sci, 2016, 73(1): 23-39.
|
60. |
Bouras E, Karhunen V, Gill D, et al. Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis. BMC Med, 2022, 20(1): 3.
|
61. |
Song J, Li A, Qian Y, et al. Genetically predicted circulating levels of cytokines and the risk of cancer. Front Immunol, 2022, 13: 886144.
|
62. |
Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol, 2013, 230(3): 241-248.
|
63. |
Yuan S, Carter P, Bruzelius M, et al. Effects of tumour necrosis factor on cardiovascular disease and cancer: a two-sample Mendelian randomization study. EBioMedicine, 2020, 59: 102956.
|
64. |
Tao S, Lin Y, Huang S, et al. Circulating inflammatory cytokines in relation to the risk of renal cell carcinoma: a gender-specific two-sample Mendelian randomization study. Cancer Med, 2023, 12(22): 21013-21021.
|
65. |
Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. Science, 2015, 350(6265): 1193-1198.
|
66. |
Savage SA. Telomere length and cancer risk: finding Goldilocks. Biogerontology, 2024, 25(2): 265-278.
|
67. |
Cao X, Huang M, Zhu M, et al. Mendelian randomization study of telomere length and lung cancer risk in East Asian population. Cancer Med, 2019, 8(17): 7469-7476.
|
68. |
Kachuri L, Saarela O, Bojesen SE, et al. Mendelian randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers. Int J Epidemiol, 2019, 48(3): 751-766.
|
69. |
Cheng Y, Yu C, Huang M, et al. Genetic association of telomere length with hepatocellular carcinoma risk: a Mendelian randomization analysis. Cancer Epidemiol, 2017, 50(Pt A): 39-45.
|
70. |
Yachida S, Mizutani S, Shiroma H, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med, 2019, 25(6): 968-976.
|
71. |
Long Y, Tang L, Zhou Y, et al. Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study. BMC Med, 2023, 21(1): 66.
|
72. |
Ma J, Li J, Jin C, et al. Association of gut microbiome and primary liver cancer: a two-sample Mendelian randomization and case-control study. Liver Int, 2023, 43(1): 221-233.
|
73. |
Li Y, Wang K, Zhang Y, et al. Revealing a causal relationship between gut microbiota and lung cancer: a Mendelian randomization study. Front Cell Infect Microbiol, 2023, 13: 1200299.
|
74. |
Mingdong W, Xiang G, Yongjun Q, et al. Causal associations between gut microbiota and urological tumors: a two-sample Mendelian randomization study. BMC Cancer, 2023, 23(1): 854.
|
75. |
Xie SH, Fang R, Huang M, et al. Association between levels of sex hormones and risk of esophageal adenocarcinoma and Barrett’s esophagus. Clin Gastroenterol Hepatol, 2020, 18(12): 2701-2709.
|
76. |
Chang J, Wu Y, Zhou S, et al. Genetically predicted testosterone and cancers risk in men: a two-sample Mendelian randomization study. J Transl Med, 2022, 20(1): 573.
|
77. |
Zhu GL, Xu C, Yang KB, et al. Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional Mendelian randomization. BMC Cancer, 2022, 22(1): 353.
|
78. |
Xu F, Chen Z. Causal associations of hyperthyroidism with prostate cancer, colon cancer, and leukemia: a Mendelian randomization study. Front Endocrinol (Lausanne), 2023, 14: 1162224.
|
79. |
Kamiza AB, Fatumo S, Singini MG, et al. Hepatitis B infection is causally associated with extrahepatic cancers: a Mendelian randomization study. EBioMedicine, 2022, 79: 104003.
|
80. |
Yuan S, Kar S, Carter P, et al. Is type 2 diabetes causally associated with cancer risk. Evidence from a two-sample Mendelian randomization study. Diabetes, 2020, 69(7): 1588-1596.
|
81. |
Tan H, Wang S, Huang F, et al. Association between breast cancer and thyroid cancer risk: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne), 2023, 14: 1138149.
|
82. |
Xiao Z, Wang Z, Zhang T, et al. Bidirectional Mendelian randomization analysis of the genetic association between primary lung cancer and colorectal cancer. J Transl Med, 2023, 21(1): 722.
|
83. |
Zhou H, Zhang Y, Liu J, et al. Education and lung cancer: a Mendelian randomization study. Int J Epidemiol, 2019, 48(3): 743-750.
|
84. |
Zhang X, Yang X, Zhang T, et al. Association of educational attainment with esophageal cancer, Barrett's esophagus, and gastroesophageal reflux disease, and the mediating role of modifiable risk factors: a Mendelian randomization study. Front Public Health, 2023, 11: 1022367.
|
85. |
Suhre K, Arnold M, Bhagwat AM, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun, 2017, 8: 14357.
|
86. |
Wu C, Zheng L. Proteomics promises a new era of precision cancer medicine. Signal Transduct Target Ther, 2019, 4: 13.
|
87. |
Ren F, Jin Q, Liu T, et al. Proteome-wide Mendelian randomization study implicates therapeutic targets in common cancers. J Transl Med, 2023, 21(1): 646.
|
88. |
Yarmolinsky J, Díez-Obrero V, Richardson TG, et al. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: a Mendelian randomization analysis. PLoS Med, 2022, 19(2): e1003897.
|
89. |
Bastarache L, Denny JC, Roden DM. Phenome-wide association studies. JAMA, 2022, 327(1): 75-76.
|
90. |
Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA, 2020, 323(9): 844-853.
|
91. |
Ochoa D, Karim M, Ghoussaini M, et al. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat Rev Drug Discov, 2022, 21(8): 551.
|
92. |
Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet, 2015, 47(8): 856-860.
|